Akebia Therapeutics, Inc.
AKBA
$1.44
$0.021.06%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -12.24M | 540.00K | 247.00K | 6.11M | -22.80M |
| Total Depreciation and Amortization | 321.00K | 318.00K | 316.00K | 314.00K | 9.35M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 21.18M | 8.02M | 16.68M | 9.71M | 12.22M |
| Change in Net Operating Assets | 21.87M | 19.23M | 5.10M | -29.73M | -3.23M |
| Cash from Operations | 31.13M | 28.11M | 22.35M | -13.59M | -4.47M |
| Capital Expenditure | -70.00K | -77.00K | -126.00K | -18.00K | -2.00K |
| Sale of Property, Plant, and Equipment | 0.00 | 0.00 | 0.00 | 172.00K | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -7.81M | -- | -- | -- | -- |
| Cash from Investing | -7.88M | -77.00K | -126.00K | 154.00K | -2.00K |
| Total Debt Issued | 0.00 | 0.00 | 0.00 | 10.00M | 0.00 |
| Total Debt Repaid | -3.77M | 0.00 | 0.00 | -462.00K | 1.00K |
| Issuance of Common Stock | 63.00K | 1.11M | 1.72M | 65.47M | 22.32M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.15M | 0.00 | 0.00 | -63.00K | 0.00 |
| Cash from Financing | -4.85M | 1.11M | 1.72M | 74.94M | 22.33M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 18.40M | 29.14M | 23.94M | 61.51M | 17.86M |